Immunocore Holdings stock (GB00BL963Z95): Recent price dip amid biotech trends

Immunocore Holdings plc shares fell 1.19% to $28.95 on May 13, 2026, reflecting year-to-date declines in the competitive biotech sector. The company focuses on innovative T cell receptor therapies.

Immunocore Holdings plc, trading under the ticker IMCR on Nasdaq, saw its stock price decline by 1.19% on Wednesday, May 13, 2026, closing at $28.95 from $29.30, according to StockInvest.us as of May 13, 2026. This move comes amid a year-to-date drop of 14.3% for the UK-based biotech firm, as noted in performance rankings from StockTitan as of 2026. Investors in the US market, where IMCR lists, continue to monitor immunotherapy developers closely.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Immunocore Holdings plc
• Sector/industry: Biotechnology / Immunotherapy
• Headquarters/country: United Kingdom
• Core markets: Oncology, infectious diseases
• Key revenue drivers: TCR-T therapies like Kimmtrak
• Home exchange/listing venue: Nasdaq (IMCR)
• Trading currency: USD

Immunocore Holdings: core business model

Immunocore Holdings plc develops proprietary T cell receptor (TCR) therapies targeting cancer and infectious diseases. Its lead product, Kimmtrak (tebentafusp), is approved for advanced uveal melanoma and generates key revenue. The platform uses engineered TCRs fused to T cell recruiting domains to direct immune responses against tumor cells. Listed on Nasdaq since 2021, the company appeals to US investors through its exposure to high-growth immuno-oncology.

Headquartered in the UK, Immunocore operates globally with a focus on precision medicine. Its ImmTAC molecules represent a novel modality distinct from CAR-T therapies, offering potential advantages in solid tumors. The business model emphasizes milestone payments, royalties, and product sales from partnerships with firms like Genentech.

Main revenue and product drivers for Immunocore Holdings

Kimmtrak remains the primary revenue driver, approved by the FDA for HLA-A*02:01-positive uveal melanoma patients. Sales growth has supported operations, though competition in oncology pressures margins. Pipeline candidates like IMC-F106C for solid tumors advance in clinical trials, with data readouts as key catalysts.

Collaborations provide non-dilutive funding and validation. For instance, deals with major pharma bolster R&D without full ownership dilution. US market access via Nasdaq listing enhances liquidity for American retail investors tracking biotech innovators.

Industry trends and competitive position

The biotech sector faces volatility in 2026, with immunotherapy stocks sensitive to clinical data and funding environments. Immunocore competes with players like Immatics (IMTX), which reported Q1 2026 revenue of €7.6 million but a €0.43 per share loss, per Simply Wall St as of 2026. Melanoma therapeutics market growth at 5.6% CAGR to 2032 underscores demand, according to sector reports.

Immunocore's TCR platform differentiates it in a crowded field, targeting intracellular antigens inaccessible to antibodies. Its position strengthens with US regulatory nods, relevant for investors eyeing oncology exposure.

Why Immunocore Holdings matters for US investors

As a Nasdaq-listed UK biotech, Immunocore offers US investors direct access to European innovation without ADR complexities. Its pipeline addresses unmet needs in rare cancers, aligning with trends in precision oncology. Year-to-date declines reflect broader biotech pullbacks, but Nasdaq trading provides familiar venue and USD denomination.

Conclusion

Immunocore Holdings navigated a 1.19% share price drop on May 13, 2026, within a 14.3% YTD decline, amid biotech sector pressures. Core TCR platform and Kimmtrak sales provide a foundation, while pipeline progress offers future potential. US investors benefit from Nasdaq access to this innovative player in immunotherapy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.